Emerald Health Sciences Inc. - Dec 31, 2021 Form 5 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
10%+ Owner
Signature
/s/ Stephen Hall
Stock symbol
SKYE
Transactions as of
Dec 31, 2021
Transactions value $
-$256,667
Form type
5
Date filed
1/31/2022, 12:58 PM
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SKYE Common Stock Sale -$257K -2.57M -2.25% $0.10 111M Aug 7, 2020 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Warrants with Credit Facility of Oct 5, 2018 Award $0 +2.5M $0.00 2.5M Nov 1, 2018 Common Stock 2.5M $0.50 Direct F1
transaction SKYE Warrants with Credit Facility of Oct 5, 2018 Award $0 +2.5M $0.00 2.5M Feb 1, 2019 Common Stock 2.5M $0.50 Direct F1
transaction SKYE Warrants with Credit Facility of Oct 5, 2018 Award $0 +2.5M $0.00 2.5M Mar 29, 2019 Common Stock 2.5M $0.50 Direct F1
transaction SKYE Multi Draw Credit Facility - T2 Award $0 +38.8K $0.00 38.8K Feb 1, 2019 Common Stock 38.8K $0.40 Direct F1, F2
transaction SKYE Multi Draw Credit Facility - T3 Award $0 +5.35M $0.00 5.35M Mar 29, 2019 Common Stock 5.35M $0.40 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transactions were previously reported on various prior Form 4 filings; however, the entries were erroneously reported as non-derivative transactions in Common Stock and the resulting reported total ownership included the misclassified securities. The entry of these transactions is to correct this error and reflect the actual securities held by the Reporting Person.
F2 The Multi Draw Credit Facility tranches have the option to convert into Common Stock upon maturity of the facilities.